B
MDGL icon

Braidwell’s Madrigal Pharmaceuticals MDGL Stock Holding History

Braidwell’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-60,781
Closed -$18.4M – 78
2025
Q2 		$18.4M Buy
60,781
+12,091
+25% +$3.6M 0.63% 40
2025
Q1 		$16.1M Buy
+48,690
New +$16M 0.57% 47
2024
Q4 		– Sell
-183,818
Closed -$39M – 87
2024
Q3 		$39M Buy
+183,818
New +$47M 1.11% 38

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

Braidwell's MDGL Position: Q3 2025 in Review

Braidwell sold out of Madrigal Pharmaceuticals (MDGL) in Q3 2025, closing a stake of 60,781 shares — an estimated $18.4M sold.

Braidwell first reported a position in MDGL in Q3 2024 and held it in 3 quarters. The position peaked at $39M in Q3 2024. 352 funds tracked by Wall St. Rank hold MDGL as of Q3 2025.

  • Braidwell reported no remaining Madrigal Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Braidwell sold 60,781 Madrigal Pharmaceuticals shares in Q3 2025, an estimated $18.4M.
  • Braidwell first reported a position in Madrigal Pharmaceuticals in Q3 2024 and held it in 3 quarters.
  • Braidwell's Madrigal Pharmaceuticals position peaked at $39M in Q3 2024.
  • 352 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q3 2025.

Based on Braidwell's 13F filing for Q3 2025, filed 14 Nov 2025.